Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib

Impacto

Downloads

Downloads per month over past year

Marcé, Sílvia and Xicoy, Blanca and García, Olga and Cabezón, Marta and Estrada, Natalia and Vélez, Patricia and Boqué, Concepción and Sagüés, Miguel and Angona, Anna and Teruel Montoya, Raúl and Ferrer Marín, Francisca and Amat, Paula and Hernández Boluda, Juan and Ibarra, Mariana and Anguita Mandly, Eduardo and Cortés, Montserrat and Fernández Ruiz, Andrés and Fontanals, Sandra and Zamora, Lurdes (2021) Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib. Journal of Clinical Medicine, 10 (14). p. 3146. ISSN 2077-0383

[thumbnail of jcm-10-03146-v2.pdf]
Preview
PDF
Creative Commons Attribution.

1MB

Official URL: https://doi.org/10.3390/jcm10143146




Abstract

The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine–kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of this study was to correlate the expression of e14a2 or e13a2 to clinical characteristics, cumulative cytogenetic and molecular responses to IM, acquisition of deep molecular response (DMR) and its duration (sDMR), progression rate (CIP), overall survival (OS), and treatment-free remission (TFR) rate. We studied 202 CML patients, 76 expressing the e13a2 and 126 the e14a2, and correlated the differential transcript expression with the above-mentioned parameters. There were no differences in the cumulative incidence of cytogenetic responses nor in the acquisition of DMR and sDMR between the two groups, but the e14a2 transcript had a positive impact on molecular response during the first 6 months, whereas the e13a2 was associated with improved long-term OS. No correlation was observed between the transcript type and TFR rate.


Item Type:Article
Uncontrolled Keywords:chronic myeloid leukemia; BCR-ABL1 transcripts; response to imatinib; survival; discontinuation; relapse-free survival
Subjects:Medical sciences > Medicine > Hematology
Medical sciences > Medicine > Oncology
ID Code:71280
Deposited On:24 Mar 2022 17:38
Last Modified:26 Mar 2022 11:46

Origin of downloads

Repository Staff Only: item control page